Actavis nabs FDA nod for Namenda combo drug; Novartis heralds psoriasis med's Japanese approval;

@FiercePharma: Pfizer's growth spurt continues with pickup of Switzerland's Redvax. FierceVaccines Story | Follow @FiercePharma

@CarlyHFierce: Indivior CEO looks beyond 2015 after troubled Reckitt pharma unit's spinoff. Story | Follow @CarlyHFierce

> Actavis ($ACT) and partner Adamas won FDA approval for Namzaric, an Alzheimer's disease therapy that combines Actavis' soon-to-go-off-patent Namenda and Aricept, marketed as a solo therapy by Pfizer ($PFE) and Eisai. Release

> Novartis ($NVS) won approval in Japan for its brand-new psoriasis treatment Cosentyx (secukinumab), for both plaque psoriasis and psoriatic arthritis. Release

> Dendreon, the once-high-flying biotech, is set to go on the block in a bankruptcy auction Feb. 3--and there will be no "stalking horse" bidder alongside to set the pace. Report

> Incoming Massachusetts AG Maura Healey says she would consider suing painkiller manufacturers over the addiction epidemic in her state, in an effort similar to Kentucky's ongoing legal battle. Report

Medical Device News

@FierceMedDev: HTG Molecular Diagnostics mulls $60M IPO for next-gen profiling technology. FierceDiagnostics story | Follow @FierceMedDev

@EmilyWFierce: Aethlon Medical snagged FDA approval for clinical trial of bio-filtration device to treat Ebola. Release | Follow @EmilyWFierce

> FDA deems Halyard's recalled KimVent endotracheal tubes potentially deadly. News

> Survey: Most U.S. consumers eager to use wearable devices to monitor their health. Report

Biotech News

@FierceBiotech: Aduro bags $51M for its 'breakthrough' cancer combo. Story | Follow @FierceBiotech

@JohnCFierce: Big round of deals today augurs well for new partnerships/ M&A in 2015. #JPM15 will be abuzz with deal talk (not unusual). #biotech | Follow @JohnCFierce

@DamianFierce: $AMGN buys into CAR-T with $KITE partnership. Release | Follow @DamianFierce

> Pfizer continues deal spree with Redvax CMV vaccine buyout. Report

> Novartis rolls toward FDA nod with a copy of Amgen's Neupogen. Article

> Bristol-Myers to collaborate with Calibr on fibrosis drugs. Item

Biotech IT News

> Scripps director: Validation needed to unlock the potential of wearables. Item

> NHS England picks 100,000 Genomes Project sites ahead of February start date. Article

> Analytics and Big Data investments spur bumper year for digital health funding. Story

> FDA outlines industry-focused ambitions as Mini-Sentinel graduates. More

> Roche buys Bina to add informatics piece to its genomics resurgence. News

CRO News

> Evotec teams up with Ohio State on a new cancer drug. Story

> WuXi goes mobile with a chemistry app. News

> GVK feels the sting after data scandal. More

> Covance could face fines over animal deaths. Story

> PPD bets on Japan with new joint venture. Article

Animal Health News

> Lilly closes Novartis deal, creating second-largest animal health giant. News

> FDA trusts vets to curb antibiotic use, but are ties to drug companies too tight? More

> High debt, low starting salaries plague new veterinarians. Item

> Colorado State nabs record $42.5M gift for translational research institute. Story

> Putney CEO Hoffman sets sights high for 'largest pipeline' in animal health. Article

And Finally... Forget risk factors; some two-thirds of cancers can be traced to random genetic changes. Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.